Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System
Key Highlights
- ➤Memorial Hermann to install OTTAVA as first U.S. commercial customer
- ➤OTTAVA received FDA De Novo authorization in July 2026
- ➤FDA authorized OTTAVA for ten upper-abdominal general surgery procedures
- ➤Johnson & Johnson will expand OTTAVA launch with select U.S. customers
Expert Statements
Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, Johnson & Johnson
“Today's milestone is a significant step for Johnson & Johnson as we commercialize OTTAVA and continue building on our ambition to lead in surgical robotics”
Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech, Johnson & Johnson
“As we bring OTTAVA to market, our focus goes beyond introducing a new technology. We will work alongside health systems and surgical teams, bringing the breadth of Johnson & Johnson to support expanding access to robotic surgery, improve workflow and procedural efficiencies, and address the evolving needs of care teams.”
Hani Abouhalka, Company Group Chair, Surgery, MedTech, Johnson & Johnson
“We designed OTTAVA around the real-world challenges facing hospitals, surgeons and care teams, and collaboration has been fundamental to that process. Working with our first commercial customer is an important step toward realizing our vision of delivering a system designed for the surgeons who use it,”
Hani Abouhalka, Company Group Chair, Surgery, MedTech, Johnson & Johnson
“Our longstanding relationship with Memorial Hermann reflects the kind of partnership we believe is essential to advancing innovation: listening closely, learning from one another and working together to turn real-world insights into meaningful innovation. We look forward to supporting their use of OTTAVA and in the generation of clinical data and real-world evidence to further support the advancement of robotic surgery.”
Erik Wilson, M.D., Chief of minimally invasive and elective general surgery at UTHealth Houston, director of bariatric surgery at Memorial Hermann-Texas Medical Center, and lead investigator for FORTE clinical study
“I am passionate about bringing new technologies into surgery. I’ve had the opportunity to see this system evolve from early development through clinical trials and I believe it will make a meaningful difference for both surgeons and patients”
Erik Wilson, M.D., Chief of minimally invasive and elective general surgery at UTHealth Houston, director of bariatric surgery at Memorial Hermann-Texas Medical Center, and lead investigator for FORTE clinical study
“This kind of collaboration is essential to advancing robotic surgery, and I’m looking forward to bringing this next chapter to Memorial Hermann.”
Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System
Commercial agreement marks the next milestone in bringing a new category of soft-tissue robotics to hospitals and patients across the United States
Get started
Create a free account to read the full story.
